Systematic Review with Meta-Analyses of Natural Products in the Treatment of Recurrent Aphthous Stomatitis

Katherine S Phillips, DDS, DABDSMi, Wallace C Carrillo Medina, DMDj, Joeseph M Potter, BA, DDSk, Kamal Al-Eryani, DDS, PhDl and Reyes Enciso, PhDm

1Advanced Graduate, Master of Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC, USA
2Assistant Professor, Division of Periodontology, Diagnostic Sciences & Dental Hygiene, Herman Ostrow School of Dentistry of USC, USA
3Associate Professor, Division of Dental Public Health and Pediatric Dentistry, Herman Ostrow School of Dentistry of USC, USA

*Corresponding author: Reyes Enciso, PhD, Associate Professor, Instructional, Division of Dental Public Health and Pediatric Dentistry, Herman Ostrow School of Dentistry of USC, 925 West 34th St, Room 4268, Los Angeles, California, USA, Fax: (213)-740-8815

Objective: Conduct a systematic review and meta-analysis of natural products in the treatment of recurrent aphthous stomatitis (RAS) and their effect on the size and pain levels compared with placebos.

Study design: Randomized placebo-controlled trials were identified up to January 2019 in PubMed, EMBASE, Web of Science and Cochrane Library. Cochrane Risk of Bias tool was used to assess the risk of bias.

Results: The search yielded 248 unduplicated references. After evaluation, 11 studies with 694 subjects with RAS were included. One was considered low risk of bias, two were considered high risk and eight were considered unclear risk. In a meta-analysis, natural products provided a statistically significant reduction in ulcer size of about -1.74 mm compared to placebo (95% CI = -3.151 to -0.327; p = 0.016); also pain intensity improved moderately with an effect size (standardized difference in means) of -0.79 (95% CI = -1.447 to -0.141; p = 0.017). Quality of evidence was moderate due to unclear/high risk of bias for ulcer size and pain intensity. The group using natural products were 2.556 times as likely to improve than placebo subjects at 3-4 days. Similar results after 5-7 days with low quality of evidence.

Conclusions: The selected group of 11 natural products included in this systematic review seem to reduce pain intensity and lesion size in RAS patients with low to moderate quality of evidence. However, due to high heterogeneity and unclear/high risk of bias, the results are inconclusive.

Keywords
Natural products, Recurrent aphthous stomatitis (RAS), Plant-based interventions, Honey, Herbal supplement, Systematic review, Meta-analysis, Randomized controlled trial, Visual analog scale

Abbreviations
RAS: Recurrent Aphthous Stomatitis; CI: Confidence Interval; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analyses; PICO: Patient Intervention Comparison Outcome; RCTs: Randomized Controlled Trials; OHIP: Oral Health Impact Profile; VAS: Visual Analog Scale; EI: Efficacy Index; RR: Risk Ratios; GRADE: Grades of Recommendation Assessment Development and Evaluation; SDM: Standardized Difference in Means

Introduction
Recurrent aphthous stomatitis (RAS) is a disorder characterized by recurring ulcers confined to the oral mucosa in patients with no other signs of disease. RAS affects approximately 20% of the general population [1]. It is the most common ulcerative disease of the oral mucosa [2]. It is more common in children with a prevalence of 39% [3]. Prevalence decreases with advancing age and increases with higher socioeconomic status and female gender [4]. A prodromal period of 2-48
hours precedes the ulceration [4]. During the prodromal period, patients may experience tingling or burning in the area where the ulceration develops. The ulcers are round and shallow with an erythematous border and white, yellow or gray pseudo membrane. The lesions occur most commonly in non-keratinized oral mucosa, such as the buccal mucosa, but may also occur on keratinized tissue like the hard palate [2-5]. The course of the lesion healing is variable, and the lesions may last days or weeks before healing is complete. The lesions can be quite painful and affect nutrition, speech and oral hygiene [3].

Other diseases such as herpes stomatitis, Behçet’s disease, Crohn’s Disease and ulcerative colitis may be considered in the differential diagnosis of intraoral ulcerations, but are different etiological entities than RAS. The precise etiology of RAS is unknown. There may be a combination of contributory factors that lead to development of RAS in each individual patient. Regardless, the etiology of RAS is multi-factorial and may be related to trauma, nutritional deficiency, allergy, altered immune response and stress [2,3]. There is also a hereditary component; children whose parents both experience RAS exhibit a 90% prevalence of the condition [3,6].

A number of treatments for RAS have been evaluated, including use of topical analgesic anti-inflammatory drugs, local anesthetics, topical antibiotics, antiseptics and topical steroids [1]. Although topical medications can be helpful, not every patient will experience satisfactory response to topical interventions. Several systemic medications have been considered for management of RAS including corticosteroids, dapsone, thalidomide and colchicine, among others [1,2,4]. Because of the possible adverse effects from systemic medications, herbal supplements and natural products have been advocated as an alternate form of treatment.

There is a growing interest among patients, clinicians and researchers as to the viability of ‘natural products’ as appropriate treatment options due to the perceived lack of side effects and the variability of response to topical medications. In this systematic review, ‘natural products’ are defined as compounds that are derived from natural sources such as plants, animals or micro-organisms [7]. A total of eleven plant-based interventions and honey (herbal supplements or natural products) have been studied in randomized controlled trials against a placebo (Table 1). The objective of this study was to conduct a systematic review and meta-analysis of natural products in the treatment of RAS and their effect on the size of RAS lesions and the pain levels compared with placebos.

### Methods and Materials

This systematic review adhered to the Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement [8].

### Inclusion and exclusion criteria

The PICO (Patient, Intervention, Comparison, Outcome) question was, in adult patients with recurrent aphthous stomatitis, do natural products (plant-based or animal-based) reduce ulcer size and pain intensity compared to placebo. Studies were limited to Randomized controlled trials (RCTs) on the efficacy of natural products to treat recurrent aphthous stomatitis in adults compared to placebo [9-19]. Synthetic supplements such as vitamins (including LongoVital—a mix of vitamins and a variety of herbs) were excluded.

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Common names</th>
<th>Mechanism of action</th>
<th>Interactions (Lexicomp)</th>
<th>Adverse reactions (Lexicomp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Satureja khuzistanica [9]</td>
<td>Mint</td>
<td>This plant has anti-spasmodic, antidiarrheal, antioxidant, anti-inflammatory, and chemotherapeutic properties.</td>
<td>None well documented.</td>
<td>The oil is strongly irritating in animal skin models, but is not phototoxic.</td>
</tr>
<tr>
<td>Proaftol (25% propolis, benzocaine, sage, peppermint, aniseed, menthol) [10]</td>
<td>Propolis (bee glue)</td>
<td>This mixture is an antibiotic with anti-inflammatory and anti-oxidant properties.</td>
<td>None well documented.</td>
<td>Allergic reactions with skin and mucous membrane irritations have been reported. Sensitization to propolis, long recognized by apiary workers, has also been reported.</td>
</tr>
<tr>
<td>Myrtle [11]</td>
<td>Periwinkle</td>
<td>Myrtle has anti-hyperglycemic, antibacterial and analgesic properties.</td>
<td>An <em>in vitro</em> study evaluated the effect of periwinkle alkaloids on the cytochrome (CYP) P450 enzyme system, and some isolated alkaloids showed potent inhibition of CYP2D6, but weak activity against CYP3A4.</td>
<td>Clinical information is lacking. Adverse reactions are documented for vinca alkaloids related to doses used in chemotherapy.</td>
</tr>
<tr>
<td><strong>Aloe vera [12,17]</strong></td>
<td><strong>Honey [13]</strong></td>
<td><strong>Rosa damascene [14]</strong></td>
<td><strong>0.65% Yunnan Baiyao [16]</strong></td>
<td><strong>Myrrh [17]</strong></td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------</td>
<td>------------------------</td>
<td>-----------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Aloe Vera is wound healing, anti-inflammatory, and anti-infection agent.</td>
<td>Hypoglycemic-associated agents: Herbs (hypoglycemic properties) may enhance the hypoglycemic effect of hypoglycemic associated agents. Monitor therapy.</td>
<td>Antioxidant, anti-inflammatory, and anti-bacterial properties have been reported for this plant.</td>
<td>This powder has anti-hemorrhagic hemostatic and wound healing properties.</td>
<td>Myrrh has anti-inflammatory and wound healing properties.</td>
</tr>
<tr>
<td>Except for dried latex, aloe is not approved as an internal medication. The external use of aloe has not been associated with severe adverse reactions; the majorities are relatively mild and reversible upon cessation. Reports of burning sensations following topical application of aloe gel to dermabraded skin have been described. Contact dermatitis from the related Aloe arborescens has been reported. Erythema, edema, urticaria, and eczematous rash have also been reported following A. vera application.</td>
<td>None well documented for honey or bee pollen. Case reports of hematuria due to potentiation of warfarin have been documented with royal jelly.</td>
<td>Nausea, indigestion, peptic ulcer, and diarrhea are some of the side-effects of these treatments.</td>
<td>None well documented</td>
<td>Myrrh may interact with warfarin and other coumarin derivatives, resulting in a reduction in the international normalized ratio (INR).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ed. Editorials, literature reviews, systematic reviews, case reports, animal studies, pilot studies, not randomized controlled trials and clinical guidelines were excluded. Reviews, systematic reviews and guidelines were scanned for relevant trials. Articles not available in English were also excluded (Table 1).

**Outcomes** The primary outcomes of this systematic review were *ulcer size* in millimeters measured with a ruler or caliper, and *pain intensity* measured with various validated scales. Secondary outcomes included *level of erythema and exudation*, measured using a 4 point scale 0-3 (*Erythema*: 0-no erythema; 1-Light red/pink; 2-Red but not dark in color; 3-Very red, dark in color. *Exudation*: 0-no exudation; 1-Light exudation; 2-Moderate; 3-heavy exudation, with pseudo membrane), based on the methods of Greer 1993 [20] with modifications by Liu, et al. [21].

The *degree of hyperemia* was also reported on a scale 0-3 as follows: 0-no hyperemia; 1-reddish; 2-deep red; 3-purplish red [19]. Another secondary outcome analyzed was the *Efficacy index* (EI) for ulcer size or pain, as defined by Meng, et al. [22] and Liu, et al. [16]. The EI was evaluated on a 4-rank scale: 1-Heal: EI = 100%; 2-Marked improvement: 100% > EI > 70%; 3-Moderate improvement: 70% > EI ≥ 30%; 4-No improvement: EI < 30%. Review authors defined a *significant improvement* as patients with an EI > 70%. Finally, *time to complete healing* in days was evaluated as well in addition to the *Oral health impact profile* (OHIP) [23]. The OHIP-14 is a 14 question questionnaire that measures people’s perception of the social impact of oral disorders on their well-being [23].

**Search criteria and strategies:** Four electronic databases (MEDLINE via PubMed, EMBASE, the Cochrane Library and Web of Science) were searched on February 8th, 2018 using the search strategies detailed in Supplement Table 1. The search was re-run on February 10th, 2019 and one new systematic review was found [24] and one RCT studying a plant-based supplement (berberine) [9].

**Data collection and analysis**

Three independent reviewers (K.S.P., W.C.C.-M., J.M.P.) analyzed all titles and abstracts for inclusion that were found through hand-searched reference lists and electronic searches. The full text versions were retrieved and analyzed if any titles or abstracts had inadequate information to decide to reject or include in the studies. A fourth reviewer (R.E.) resolved any disagreements during discussions about inclusion or rejections of studies that had lack of consensus. Each abstract had reasons for exclusion clearly outlined. Inclusion and exclusion criteria, number of participants, demographics and other data on study participants’ characteristics were gathered during the qualitative synthesis phase. A standardized table was used to extract this data along with the interventions and outcomes that were assessed in each study.

Assessment of risk of bias was undertaken independently by three reviewers (K.S.P., W.C.C.-M., J.M.P.) guided by the Cochrane risk-of-bias tool [25]. Arisk of bias table was completed for each included study.

**Meta-analyses**

Studies reporting similar outcomes comparing natural products’ group to placebo group in RCTs of patients with RAS were included in meta-analyses. Random-effects model was chosen due to the heterogeneity of the interventions (i.e. different natural products). Difference in means and 95% Confidence intervals (CI) were reported for outcomes ulcer size in mm and level of erythema and exudation at different time points. Standardized difference in means (SDM) and 95% CI were reported for pain intensity due to the use of three different pain scales by the studies. Risk ratios (RR) with 95% CI were reported for binary outcome significant improvement in ulcer size (yes/no) defined as an efficacy index of > 70%. All analyses were performed using Comprehensive Meta-analysis software v2 (Bio stat, Englewood, NJ, USA).

**Levels of evidence and summary of the review findings**

Quality of evidence assessment and summary of the review findings were conducted with the software GRADE profiler® (Grader®), following the Cochrane Collaboration and GRADE Working Group recommendations [25]. In this systematic review we downgraded the quality of the evidence due to unclear/high risk of bias or due to imprecision (only two studies reporting the outcomes with less than 400 participants in total included in the meta-analysis [26]).
Table 2: Summary of eligible RCT studies.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Country, Study Type, Total sample size</th>
<th>Interventions, sample size per group</th>
<th>Control intervention, sample size</th>
<th>Inclusion criteria</th>
<th>Gender and age (average ± SD, range in years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amanlou, et al. [11]</td>
<td>Iran, RCT, double blinded, N = 60</td>
<td>S. khuzistanica extract 3x day, n = 20</td>
<td>S. khuzistanica essential oil, n = 20</td>
<td>(1) History of RAS (2) Currently suffering from ulceration located on the oral mucosa</td>
<td>28M/32F 28.48 10-64 years</td>
</tr>
<tr>
<td>Atanasovska Stojanovska, et al. [13]</td>
<td>Macedonia, RCT, double blinded N = 20</td>
<td>Proaftol spray, n = 10</td>
<td>Control spray, n = 10</td>
<td>(1) RAS with a frequency of at least 3-4 times a year.</td>
<td>No gender specified 20-30 years</td>
</tr>
<tr>
<td>Babaee, et al. [14]</td>
<td>Iran, randomized, double-blind, controlled before-after clinical trial N = 40</td>
<td>Myrtle oral paste, n = 40</td>
<td>Placebo oral paste, n = 40</td>
<td>(1) 18 years of age or older, (2) Clear history of RAS occurring at least twice a year, (3) Presenting with 1-3 aphthous ulcers (&lt; 48 h duration), measuring no more than 10 mm in diameter, (4) Had an expectation that their ulcers normally takes &gt; 5 days to resolve without treatment, (5) No underlying medical or hematological cause for their ulceration.</td>
<td>17M/23 F 29.5 ± 10.3 18-58 years</td>
</tr>
<tr>
<td>Babaee, et al. [15]</td>
<td>Iran, RCT, double blinded N = 40</td>
<td>Aloe vera gel, n = 20</td>
<td>Placebo gel, n = 20</td>
<td>(1) Aged between 15 and 35 years (2) Minor recurrent aphthous singular lesions on their buccal mucosa and mucosal zone of the lips (after a medical diagnosis of RAS minor) (3) Without any other medical complications (4) Patients had noticed oral lesions during the last two days</td>
<td>22M/18F Intervention group: 27.95 ± 7.96 years Placebo: 29.25 ± 7.48 years</td>
</tr>
<tr>
<td>El-Haddad, et al. [16]</td>
<td>Kingdom Saudi Arabia, RCT, single-blinded N = 94</td>
<td>Honey-treated group, n = 34 0.1% triamcinolone acetonide, n = 30</td>
<td>Orabase control group, n = 30</td>
<td>(1) Males and females aged from 18-60 years old. (2) Positive history of recurrent aphthous ulceration that normally last more than 5 days each episode without treatment. (3) Presence of 1-5 aphthous ulcers that present for less than 48 hours without treatment. (4) Ulcer size not greater than 5 mm in diameter. (5) The ulcers are available for topical application of the treated agent.</td>
<td>28M/66F 18-60 years</td>
</tr>
<tr>
<td>Study Authors/Location</td>
<td>Study Design/Design Type</td>
<td>Study Sample Size</td>
<td>Treatment</td>
<td>Placebo</td>
<td>Inclusion Criteria</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------------------</td>
<td>-------------------</td>
<td>-----------</td>
<td>---------</td>
<td>-------------------</td>
</tr>
</tbody>
</table>
| Hoseinpour, et al. [17] | Iran, RCT, double-blind | N = 50 | Mouth wash with Rosa damascene 1 minute, N = 25 | Placebo, n = 25 | (1) At least one aphthous ulcer measuring no more than 10 mm in diameter; 
(2) Duration of the ulcer(s) ≤ 48 hours; 
(3) Only patients with minor or herpetic form ulcerations were included. |
| Jiang, et al. [10]     | China, RCT, double-blind | N = 84 | Berberine gelatin (10 g) containing 50 mg berberine, n = 42 | Placebo agent, n = 42 | (1) Both genders aged 18 to 50 years; 
(2) A history of RAS for a minimum of 6 months with an average of 1 to 2 outbreaks per month and 1 to 5 minor aphthae per outbreak; 
(3) No analgesics use or other drugs curing oral ulcer during the study; 
(4) 1 to 3 aphthous ulcerations with a size _5 and _10 mm in diameter; for more than 1 ulceration, a distance between ulcerations of more than 1 cm; 
(5) Time of ulceration onset within 48 hours; 
(6) Ulcers in locations that are easily accessible for evaluation and treatment. |
| Liu, et al. [18]       | China, RCT, double-blind | N = 240 randomized, N = 227 completed the study | Toothpaste 0.65% Yunnan Baiyao, n = 113 | Placebo toothpaste, n = 114 | (1) Both male and female aged 18 to 65-years-old; 
(2) Patients diagnosed as minor recurrent aphthous stomatitis with the duration of each ulcer in excess of 5 days; 
(3) Fresh ulcers available with less than 72 hours eruption. |
| Mansour, et al. [19]   | Saudi Arabia, RCT, double-blind | N = 90 | Mucoadhesive gel with aloe vera, n = 30 | Mucoadhesive gel (placebo), n = 30 | (1) Presenting with 1-3 minor fresh RAS lesions, with duration < 48 h, and not greater in diameter than 5 mm. 
(2) If any participant had more than one ulcer, the one selected for evaluation was the most recent one. |
| Pourahmad, et al. [20] | Iran, RCT, double-blind | N = 93 | Camel thorn distillate, n = 49 | Distilled water, n = 44 | (1) An aphthous lesion on their oral mucosa; 
(2) History of recurrent similar lesions. |
Results

Results of the search

The initial search strategy yielded 244 unduplicated references plus four references resultant from cross-referencing the bibliography sections of included studies and reviews. 248 references were assessed independently by three review authors, and based on the abstracts and titles these were reduced to 40 relevant manuscripts. All the 40 manuscripts identified were searched for full-
text and analyzed for inclusion independently by three review authors. 11 manuscripts were relevant for inclusion. Table 2 shows a list of our included studies. Main reasons for exclusion for 29 references are reported in PRISMA flowchart (Figure 1).

### Included studies

Ten double-blinded RCTS [9-13,15-19], and one single blinded study [14] were eligible for qualitative analysis to answer the question of efficacy of nutraceuticals on the treatment of Recurrent aphthous ulcers (RAS) (Table 2).

**Population:** A total of 694 patients were included in this review. All studies enrolled patients at only one center, and enrolled both male and female with more females overall [9-19]. The number of patients enrolled in each study ranged from 20 [11] to 217 [16]. The ages of the patients ranged from 10 [10] to 64 [10]. The inclusion criteria among the studies as well as the average age and gender distribution are presented in Table 2. Patients from the studies had a diagnosis of recurrent aphthous ulcers with present clinical signs and symptoms of ulcerations on the oral mucosa and history of RAS. Inclusion criteria in some studies specified lesions’ minimum size, duration of lesion, time of onset and other characteristics as listed in Table 2.

**Interventions:** A total of eleven interventions were evaluated in this systematic review: *Satureja khuzistanica* [10], proaftol [11], myrtle [12], aloe vera [13,17], honey [14], rosa domascena [15], Yunnan baiyao [16], myrrh [17], camel thorn [18], berberine [9] and puidiankeyanning [19]. The carriers utilized included a paste, mixture, gel or spray applied directly to the lesion [10], a mouth rinse [13], and toothpaste [13].

**Comparison groups:** Patients in the comparison groups were labeled as controls and were provided placebos that contained inert ingredients. In two studies efforts were made to ensure that the placebo resembled the intervention in color and consistency [9,15,19]. The remaining eight studies did not designate if that was also done [10-14,16-18].

**Outcomes:** The primary outcome reported by the included studies was ulcer size in mm, measured using a sterile calibrated dental probe with millimeter marking [9,12,14-18] or a metal caliper [13]. Another primary outcome was pain intensity measured with various scales: Visual analog scale (VAS) on a 100 mm line labeled at one end “no soreness” and the other end “worst possible soreness” [9,12] or a 10 mm scale [13,17,19]; pain intensity on a 0-3 scale with 0-no pain, 1-discomfort, 2-moderate pain and 3-severe pain [11-15]. Secondary outcomes included level of erythema and exudation were reported in three studies [9,12]. One study reported only average degree of erythema without any other information (i.e. standard deviation, percentiles) and could not be included in the meta-analysis [14]. One study [19] reported the degree of hyperemia on a scale 0-3 and could not be included in the meta-analysis as it is a different outcome than erythema and exudation combined. Another secondary outcome measured was the Efficacy index (EI) for ulcer size or pain, as defined by Meng, et al. [22] and Liu, et al. [16]. The EI was evaluated for ulcers’ size in two studies [15,16] and for pain in one study [16]. Three outcomes were only evaluated...
in one study, time to complete healing [10,18], dates of pain elimination [10], and Oral health impact profile (OHIP) [12] and no meta-analysis could be undertaken.

Risk of bias in included studies

A summary of risk of bias table (Supplement Table 2) as well as a risk of bias graph (Figure 2) are presented in this review.

Random sequence generation: Method was identified as low risk of bias in six studies total [9,14-17,19] because they used a computer based random number generator. Five studies [10-13,18] were unclear risk for random sequence generation because they didn’t specify the method they used. No studies were high risk.

Allocation concealment was considered low bias for six studies [9,12,14-16,18] because the treatment assignments were hidden from both patients and investigators or a third party recorded the randomized codes and were not involved in the study. Five studies [10,11,13,17,19] were considered unclear risk for allocation concealment because the studies allocation concealment methods were not described.

Blinding Two studies [12,15] were considered to be low risk for blinding because the authors clearly stated that after selection, patients randomly assigned a number and were allocated to the placebo or experimental group were blinded as were the investigators delivering treatment, as were the outcome assessors and the analysts. The randomly assigned number was recorded in the protocol, and information regarding the contents

![Image](image-url)

**Figure 3:** Meta-analyses for ulcer size in mm. A,B) Ulcer size was significantly decreased at days 3-4 and days 5-7 in the intervention groups compared to the placebo group.
studies [11,14] had high risk for incomplete outcome data because all data does not seem to be completely addressed, intent to treat analysis is not stated, or number of drop outs or reasons for drop outs are not stated. Four studies [9,10,12,18] were considered to have an unclear risk of bias for incomplete outcome data, intent to treat analysis not clearly stated or because the number of dropouts were stated, but the reason was not clear.

**Incomplete outcome data:** Five studies [13,15-17,19] included had no missing outcome data and were assessed as being at low risk of bias for this domain. Two studies [11,14] had high risk for incomplete outcome data because all data does not seem to be completely addressed, intent to treat analysis is not stated, or number of drop outs or reasons for drop outs are not stated. Four studies [9,10,12,18] were considered to have an unclear risk of bias for incomplete outcome data, intent to treat analysis not clearly stated or because the number of dropouts were stated, but the reason was not clear.

**Selective reporting:** All of the pre-specified outcomes were reported in the pre-specified way in all studies.
Meta-analyses results

The primary outcome measures reported by the authors were the differences in post-treatment ulcer size (mm) and pain intensity. Secondary outcomes included significant improvement in ulcer size at 3-4 days and 5-7 days and level of erythema and exudation (scale 0-3). All results reported used the random-effects model.

Ulcer size (mm): Six studies reported mean and standard deviation of ulcer size at 3-4 days [11,13,15,17-19]. Natural products provided a statistically significantly better reduction in ulcer size (mm) compared to placebo (Difference in means = -1.739; 95% CI = -3.151 to -0.327; p = 0.016) (Figure 3a). Similar results were found at 5-7 days (Figure 3b).

Pain intensity: Six studies reported mean and standard deviation of pain intensity at 3-4 days [11-14,16,19]. Due to different pain scales reported by

### Table A

<table>
<thead>
<tr>
<th>Study name</th>
<th>Risk ratio</th>
<th>Lower limit</th>
<th>Upper limit</th>
<th>Z-Value</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hoseinpour et al. 2011</td>
<td>4.200</td>
<td>1.883</td>
<td>9.370</td>
<td>3.505</td>
<td>0.000</td>
</tr>
<tr>
<td>Liu et al. 2012</td>
<td>1.737</td>
<td>1.034</td>
<td>2.920</td>
<td>2.085</td>
<td>0.037</td>
</tr>
<tr>
<td></td>
<td>2.556</td>
<td>1.084</td>
<td>6.030</td>
<td>2.144</td>
<td>0.032</td>
</tr>
</tbody>
</table>

Random-effects model

<table>
<thead>
<tr>
<th>Study name</th>
<th>Risk ratio</th>
<th>Lower limit</th>
<th>Upper limit</th>
<th>Z-Value</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hoseinpour et al. 2011</td>
<td>1.889</td>
<td>1.300</td>
<td>2.745</td>
<td>3.335</td>
<td>0.001</td>
</tr>
<tr>
<td>Liu et al. 2012</td>
<td>1.327</td>
<td>1.059</td>
<td>1.663</td>
<td>2.460</td>
<td>0.014</td>
</tr>
<tr>
<td></td>
<td>1.532</td>
<td>1.091</td>
<td>2.152</td>
<td>2.463</td>
<td>0.014</td>
</tr>
</tbody>
</table>

Random-effects model

**Figure 5:** Meta-analysis for significant improvement in ulcer size. A) Patients using natural products were 2.556 times as likely to significantly improve compared to placebo at days 3-4 and B) 1.532 times as likely to improve at days 5-7.
the authors, the effect size reported for pain intensity was the ‘Standardized difference in means’ (SDM). Cohen suggested that an absolute value of SDM between 0.2 and 0.8 be considered a ‘moderate’ effect size, and a SDM > 0.8 to be a ‘large’ effect. Natural products showed significantly better reduction in pain intensity compared to placebo at 3-4 days (SDM = -0.794; 95% CI = -1.447 to -0.141; p = 0.017) (Figure 4a) and at day 6 (SDM = -1.094; 95% CI = -1.709 to -0.479; p < 0.001) (Figure 4b).

**Significant improvement in ulcer size:** Two studies [15,19] reported significant improvement in ulcer size. They paired EI = 100% and EI = 70-100% categories as considered significant improvement of ulcer and EI = 0-30% and EI = 30-70% as non-significant improvement [15,19]. The patients using natural products were 2.556 times as likely to improve than subjects using placebo at 3-4 days (Risk ratio (RR) = 2.556; 95% CI = 1.084 to 6.030; p = 0.032) (Figure 5a) and 1.532 times as likely to improve than subjects using placebo at 5-7 days (RR = 1.532; 95% CI = 1.091 to 2.152; p = 0.014) (Figure 5b).

**Level of erythema and exudation:** Two studies [9,12] reported level of erythema and exudation on a 0-3 scale. We found no significant improvement in level of erythema and exudation at day 2 nor day 6 (Supplement Figure 1).

**Summary of the evidence and quality of the findings (GRADE):** Quality of evidence was moderate due to unclear/high risk of bias for ulcer size and pain intensity at 3-4 days and 5-7 days. Quality of evidence was low due to unclear/high risk of bias and imprecision for outcomes ‘significant improvement in ulcer size’ and ‘level of erythema and exudation’ with only two studies reporting the outcomes with less than 400 participants in total included in the meta-analysis [26]. Moderate evidence grading indicates that further research is **likely** to have an important impact on our confidence in the estimate of effect and may change the estimate. Low evidence grading indicates that further research is **very likely** to have an important impact on our confidence in the estimate of effect and it is likely to change the estimate (Table 3).

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No of participants (studies) Follow up</th>
<th>Quality of the evidence (GRADE)</th>
<th>Relative effect (95% CI)</th>
<th>Anticipated absolute effects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Risk with placebo Risk difference with Natural products (95% CI)</td>
</tr>
<tr>
<td>Ulcer size 3-4 days (mm)</td>
<td>373 (7 studies) 3-4 days</td>
<td>⊕⊕⊕⊝ MODERATE¹ due to risk of bias</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The mean ulcer size at 3-4 days in the intervention groups was -1.739 mm lower than the placebo groups (-3.151 to -0.327 lower)</td>
</tr>
<tr>
<td>Ulcer size 5-7 days (mm)</td>
<td>373 (7 studies) 3-4 days</td>
<td>⊕⊕⊕⊝ MODERATE¹ due to risk of bias</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The mean ulcer size at 5-7 days in the intervention groups was -1.873 mm lower than the placebo groups (-3.393 to -0.352 lower)</td>
</tr>
<tr>
<td>Pain intensity at 3-4 days Various scales</td>
<td>373 (7 studies) 3-4 days</td>
<td>⊕⊕⊕⊝ MODERATE¹ due to risk of bias</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The mean pain intensity at 3-4 days in the intervention groups was -0.794 standard deviations lower (-1.447 to -0.141 lower)</td>
</tr>
<tr>
<td>Pain intensity at 5-7 days Various scales</td>
<td>373 (7 studies) 5-7 days</td>
<td>⊕⊕⊕⊝ MODERATE¹ due to risk of bias</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The mean pain intensity at 5-7 days in the intervention groups was -1.094 standard deviations lower (-1.709 to -0.479 lower)</td>
</tr>
<tr>
<td>Significant improvement in ulcer size at 3-4 days</td>
<td>277 (2 studies) 3-4 days</td>
<td>⊕⊕⊝ LOW¹ ² due to imprecision and risk of bias</td>
<td>RR 2.556 (1.084 to 6.030)</td>
<td>165 per 1000</td>
</tr>
<tr>
<td>Significant improvement in ulcer size at 5-7 days</td>
<td>277 (2 studies) 6 days</td>
<td>⊕⊕⊝ LOW¹ ² due to imprecision and risk of bias</td>
<td>RR 1.532 (1.091 to 2.152)</td>
<td>504 per 1000</td>
</tr>
<tr>
<td>Level of erythema and exudation at day 2 (scale 0-3)</td>
<td>162 (2 studies) 2 days</td>
<td>⊕⊕⊕⊕ LOW1,2 due to imprecision and risk of bias</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Level of erythema and exudation at day 6 (scale 0-3)</td>
<td>162 (2 studies) 6 days</td>
<td>⊕⊕⊕⊕ LOW1,2 due to imprecision and risk of bias</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence.**

- **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.
- **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- **Very low quality:** We are very uncertain about the estimate.

1 Only two studies reported this outcome with small sample size < 400 participants
2 Only two studies reported this outcome with small sample size < 400 participants

CI: Confidence Interval; RR: Risk Ratio; NA: Not Available.

**Discussion**

**Summary of main results**

Ten double-blinded RCTS [9-13,15-19], and one single blinded study [14] were eligible for qualitative analysis to answer the question of efficacy of natural products on the treatment of RAS. A total of eleven interventions (plant-based and honey) were under study in the included RCTs [9-19]. One study [15] was considered low risk, two studies [11,14] were considered at high risk of bias and eight studies were considered unclear risk [9,10,12,13,16-19] (Supplement Table 2 and Figure 2).

Natural products provided significantly better reduction in *ulcer size* (mm) at 3-4 days (p = 0.016) and 5-7 days (p = 0.016) compared to placebo. The group using natural products showed *significant improvement* in ulcer size compared to placebo at 3-4 days (p = 0.032). At 5-7 days, people using natural products were 1.532 times as likely to improve than subjects using placebo (p = 0.014). Compared to dexamethasone, a clinical study reported that dexamethasone shows significant ulcer size reduction at day 6 (p < 0.001) compared to placebo, but no data was reported before day 6 [27]. These results seem to make natural products an alternative to the more commonly used corticosteroid. However, the clinical relevance of the ulcer size might not be as important to patients as it is pain reduction.

Drugs like trimacinolone ointment and dexamethasone, have been reported to be more effective than placebo in reducing pain (p < 0.01 for trimacinolone, p = 0.001 for dexamethasone) [27]. In our systematic review, natural products showed significantly better reduction in *pain intensity* (various pain scales reported) compared to placebo at 3-4 days (p = 0.017) with similar results at 5-7 days (p < 0.001). These results do not necessarily imply a clinical significance to the patient, and further studies are necessary to corroborate the results of this systematic review.

**Agreements and disagreements with other studies or reviews**

The results of this systematic review agree with a systematic review published in 2018 by Heydarpour, et al. evaluating plant derived topical interventions for the treatment of RAS [28]. The primary difference between our review and Heydarpour, et al. [28] review is that ours included a meta-analysis of the interventions. Heydarpour, et al. [28] evaluated non-pharmaceutical interventions in the treatment of RAS and reached the following conclusion: Due to the complex etiology of RAS, the unpredictability of outcomes resolution with current treatment modalities and the potential for adverse effects associated with systemic medicaments, local treatments with fewer side effects are desired and greater numbers of studies evaluating these treatments are needed. Another review by Hamedi, et al. conducted in 2016 also evaluated plant based interventions for the treatment of RAS [29]. The focus of Hamedi, et al. [29] review was the mechanisms by which the plants may exert their benefits pharmacologically. The effects of the plants evaluated included antibacterial, anti-inflammatory, immune modulatory and anti-viral benefits.

In our systematic review, when evaluating primary outcome measures, the natural products under study yielded improvements in pain level and lesion size. The Heydarpour, et al. review yielded similar results. No significant side effects were revealed, only slight side
effects such as mild burning sensation (S. khuzistanica) and slight-to-moderate irritation (A. vulgaris), which spontaneously relieved. Combining the results of these two reviews indicates that there is both a subjective and objective benefit derived from utilization of plant-based, non-pharmaceutical interventions.

**Heterogeneity of the review**

Review authors tried to minimize heterogeneity by including only studies with patients with RAS receiving a natural product or placebo, excluding vitamins and products with herbs and vitamins (such as LongoVital). However, some heterogeneity was present; in particular, there were different interventions in all studies and no consistent use of standard in diagnosis of RAS. Furthermore, measurements were not taken at the same intervals for RAS ulcer size and pain intensity in all studies. In addition, parameters were not similar in all studies in what constitutes RAS and by whom it was diagnosed by. There was some heterogeneity in the fact that pain intensity was measured with various scales and also the days at which the lesions’ size and pain were measured.

**Overall completeness and applicability of evidence**

Four electronic databases were searched, MEDLINE via PubMed, the Web of Science, the Cochrane Library and EMBASE up through January 2019. All included studies, reviews and systematic reviews were cross-referenced for relevant trials. Three reviewers (W.C.C., K.S.P., J.M.P.) individually assessed abstracts and titles to determine eligibility. Articles not available in English were excluded. The results of this systematic review are applicable to males and females, 10 to 64-years-old, diagnosed with RAS.

**Quality of the evidence**

Only randomized controlled trials (ten double-blinded RCTs [9-13,15-19], and one single blinded study [14]) were eligible for qualitative analysis to answer the question of efficacy of natural products on the treatment of RAS by choice of the authors, as high-quality RCTs can provide the best evidence in comparing the effects of natural products to placebo on pain and ulcer size in RAS. However, of the 11 RCTs included in the qualitative analysis, one study [15] was considered low risk, two studies [11,14] were considered at high risk of bias and eight studies were considered unclear risk [9,10,12,13,16-19]. The quality of the evidence was very low to moderate due to risk of bias, small total sample size of only 694 participants, small number of eligible studies in each meta-analysis due to heterogeneity of the outcomes reported and in some cases, wide variance of point estimates and statistical heterogeneity. In particular, there were different interventions in all studies and no consistent use of a standard in diagnosis of RAS. Furthermore, measurements were not taken at the same intervals for RAS ulcer size and pain in all studies. In addition, parameters were not similar in all studies in what constitutes RAS and by whom it was diagnosed by.

**Implications for research**

Natural products may be effective in the treatment of RAS, but greater research focus needs to be placed on specific protocols, the nature of the intervention, patient access to the intervention and clinical relevance. Although the medicaments evaluated in this analysis yielded positive results, it was unclear whether these results would be applicable clinically. Meta-analyses indicated that those interventions that showed greater efficacy over placebo reduced lesion pain and lesion longevity by such a small degree and short timeframe, that investment in these medicaments may not be worthwhile from a clinical standpoint. Future studies may produce a specific regimen of non-pharmaceutical interventions that can be combined with pharmaceutical medicaments, may develop a protocol that leads to prevention of lesions, may result in a method of adjunctive use of non-pharmaceutical topical interventions, or may lead to the development of a new drug that is entirely plant-based that has both high efficacy and low risk of adverse events. Further research should also include possible drug-drug interactions.

**Conclusions**

The utilization of natural products for the treatment of ailments is not new. Despite still being a popular option, the data supporting their use is limited. In this systematic review, we analyzed the available data for a selected group of natural products, plant-based and honey. In general, these natural products provided a significantly better reduction in ulcer size and pain compared to placebo when used for the treatment of RAS. However, these results should be taken cautiously since most of the studies were assessed at unclear risk of bias and the studies were heterogeneous. These results do not necessarily imply a clinical significance to the patient, and further studies with good quality methodology are needed for each particular natural product.

**Acknowledgments**

The authors have no funding and no conflicts of interest.

**Sources of Support**

None.

**Conflicts of Interest**

None.

**Statement of Equal Authors’ Contribution**

All authors contributed to the design and imple-
mation of the systematic review and writing of the manuscript. Dr. Enciso is responsible for the statistical analyses.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**References**


**Supplement Figure 1:** Meta-analysis for level erythema and exudation at A) Day 2 and B) Day 6.
Database | Search strategy
--- | ---
MEDLINE via PubMed (searched on 2/8/2018 and 2/10/2019) limited to English language and Humans | (Herbal supplement’ or dietary supplement’ or nutraceutical’ or vitamin’ or multivitamin’ or perilla oil or longovital or camel thorn or zinc sulphate or beta-glucan or bee-propolis or “drugs, chinese herbal” [Mesh] or “plant extracts” [Mesh] or “dietary supplements” [Mesh] or honey or “complementary therapies” [Mesh] or aloe vera or myrrh or “sapogenins/therapeutic use”[MAJR] or medicinal plants or “plants, medicinal” [Mesh]) and (recurrent aphthous stomatitis or recurrent aphthous ulcer” or “stomatitis, aphthous” [Mesh])
The Web of Science (searched on 2/8/2018 and 2/10/2019) | Topic: (Herbal supplement’ or dietary supplement’ or nutraceutical’ or vitamin’ or multivitamin’ or perilla oil or longovital or camel thorn or zinc sulphate or beta-glucan or bee-propolis or plant extract or chinese herbal or honey or complementary therapies or aloe vera or myrrh or medicinal plant’) and topic: (recurrent aphthous stomatitis or recurrent aphthous ulcer’)
The Cochrane Library (searched on 2/8/2018 and 2/10/2019) | #1. (Herbal supplement’ or dietary supplement’ or nutraceutical’ or vitamin’ or multivitamin’ or perilla oil or longovital or camel thorn or zinc sulphate or beta-glucan or bee-propolis or plant extract’ or chinese herbal or honey or complementary therapies or aloe vera or myrrh or medicinal plant’) #2. (Recurrent aphthous stomatitis or recurrent aphthous ulcer’)
EMBASE (searched on 2/8/2018 and 2/10/2019) | #1. ‘Herbaceous agent’ or ‘nutraceutical’ or ‘dietary supplement’ or ‘chinese drug’ or ‘chinese herb’ or ‘vitamin’ or ‘plant extract’ or ‘alternative medicine’ or ‘medicinal plant’ or (perilla and oil) or logovital or (camel and thorn) or (zinc and sulphate) or ‘beta glucan’ or ‘bee propolis’ or honey or (aloe and vera) or myrrh #2. ‘aphthous stomatitis’ #3. #1 and #2 #4. #3 and (‘clinical trial’/de or ‘controlled clinical trial’/de or ‘double blind procedure’/de or ‘evidence based medicine’/de or ‘major clinical study’/de or ‘randomized controlled trial’/de or ‘randomized controlled trial (topic)’/de or ‘systematic review/de)"

Supplement Table 2: Summary of risk of bias for eligible RCT studies.

<table>
<thead>
<tr>
<th>Study</th>
<th>Random seq. generation</th>
<th>Allocation concealment</th>
<th>Blinding</th>
<th>Incomplete outcome data</th>
<th>Selective reporting</th>
<th>Other potential bias</th>
<th>Overall bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>El-Haddad, et al. [16]</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>?</td>
<td>+</td>
</tr>
<tr>
<td>Hoseinpour, et al. [17]</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Liu, et al. [18]</td>
<td>-</td>
<td>-</td>
<td>?</td>
<td>-</td>
<td>-</td>
<td>?</td>
<td>?</td>
</tr>
</tbody>
</table>

Key: - low; + high risk; ? unclear.